Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis

NCT ID: NCT00755950

Last Updated: 2021-04-23

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-10-31
• Study Completion Date: 2015-12-31

Brief Summary

The purpose of this study is to assess whether two higher doses (280mg or 420mg three times daily)of silymarin therapy are safe and tolerable, and shorten the illness in patients with acute viral hepatitis compared to placebo.

Detailed Description

Currently, acute viral hepatitis (AVH) management is based on diet and rest and silymarin remains among the most popular herbs being used for treating viral hepatitis both in the U.S. and abroad. Although numerous randomized clinical trials have been conducted to assess the efficacy of silymarin on chronic hepatitis C, very few studies were done to assess the efficacy of silymarin in acute viral hepatitis. Among those, efficacy of silymarin has not been established. This could be attributed to the small number of studies conducted, small sample sizes, high drop out rates, and low doses of silymarin used. Therefore, it is justified to evaluate silymarin safety and efficacy using higher doses than previously studied in AVH.

Primary safety objective:

• To assess safety and tolerability of two silymarin doses in patients with AVH as determined by the number and percentage of subjects who develop Adverse Events in each group elicited by a questionnaire administered at specific visits and by hematology, blood chemistry and physical examinations.

Primary efficacy objective:

• To assess the percentage of subjects who normalize their total and direct bilirubin in each group.

Secondary Objective:

To assess the percentage of subjects in each group who:

• Normalize their liver enzymes, i.e. alanine aminotransferase (ALT), aspartate aminotransferase (AST) and inflammatory reactants, i.e. erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
• Resolve their clinical symptoms of AVH and return to baseline activity levels and quality of life (QOL) assessed by physical examinations and using a previously evaluated Arabic-translated SF-36 form adapted for use with patients with liver diseases.

To assess:

• Differences in silymarin response in different AVH etiologies (i.e. HAV, HBV, HCV, HEV) using subgroup analyses.

To compare:

• Progression of acute to chronic HCV infection in subjects with HCV-caused acute AVH.

Conditions

Acute Hepatitis A; Acute Hepatitis B; Acute Hepatitis C; Acute Hepatitis E; Acute EBV Hepatitis; Acute CMV Hepatitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: QUADRUPLE

Study Groups

1

280 mg of Silymarin administered three times daily for 4 weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)

Group Type: EXPERIMENTAL

Silymarin

Intervention Type: DIETARY_SUPPLEMENT

280 mg three times daily for four weeks

3

Placebo: Lactose monohydrate; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)

Group Type: PLACEBO_COMPARATOR

Lactose monohydrate

Intervention Type: OTHER

Lactose monohydrate 326.95 mg three times daily for four weeks

2.

420 mg silymarin three times daily for four weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)

Group Type: EXPERIMENTAL

Silymarin

Intervention Type: DIETARY_SUPPLEMENT

420 mg three times daily for four weeks

Interventions

Silymarin

280 mg three times daily for four weeks

Intervention Type: DIETARY_SUPPLEMENT

Silymarin

420 mg three times daily for four weeks

Intervention Type: DIETARY_SUPPLEMENT

Lactose monohydrate

Lactose monohydrate 326.95 mg three times daily for four weeks

Intervention Type: OTHER

Other Intervention Names

Legalon, Milk Thistle or St. Mary's Thistle; Legalon, Milk Thistle or St. Mary's Thistle

Eligibility Criteria

Inclusion Criteria

• Diagnosis of acute viral hepatitis (<1 month) as manifested by a combination of the following symptoms: jaundice, dark-colored urine, light-colored stools, pruritus, pruritic red hives, fever, nausea, vomiting, anorexia, aversion to smoking and right upper abdominal discomfort, pain or feeling of pressure.
• Serum ALT level > 2.5 times the upper limit of normal.
• Albumin level >3.5 gm/dl
• Negative anti-HCV antibody
• Males and females >= 18 years of age.
• Subject has given written informed consent. If patient is between 18 and 21 years parents/legal guardian have/has also signed the informed consent form.
• The subject is able and willing to undertake all study-required procedures and has the ability to take oral medications.

Exclusion Criteria

• Subjects < 18 years of age
• Pregnant or breastfeeding women
• Suspected hypersensitivity to silymarin or multivitamins
• Advanced liver disease (e.g. ascites, bleeding esophageal varices and hepatic encephalopathy)
• Chronic liver disease as cirrhosis
• Subjects with positive anti-HCV antibody
• Simultaneous elevation of bilirubin > 10 mg/dl along with an ALT level between 100 and 150 U/L
• Platelets count <150,000
• Subjects with morbid obesity i.e. a Body Mass Index (BMI) > 40
• Subjects with severe illness, e.g., multisystem failure, cancer or poorly controlled diabetes i.e. known diabetic with Hemoglobin A1C (HbA1C)>7%
• Obvious history of drug-induced acute hepatitis. A careful history of all medications, pesticide and other hepatotoxic exposures occurring within one month prior to symptom onset will be taken. If a patient is unaware of the name of the drugs, (s)he will be asked to bring it for inspection.
• Current use of Silymarin or recent use within past two weeks.
• Other conditions, which in the opinion of the investigators, makes the patient unsuitable for enrollment or could interfere with his/her participation in, and completion of, the protocol (e.g. severe mental illness)
• The subject is currently participating in any clinical trial (marketed product or otherwise), or has done so within 30 days or 5 half-lives (whichever is longer) prior to screening visit
• History or current drug or alcohol abuse
• Female patient with childbearing potential without negative pregnancy test
• Patient is known to be HIV positive.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MADAUS GmbH

OTHER

Sponsor Role: collaborator

The Egyptian Company for Blood Transfusion Services

OTHER

Sponsor Role: collaborator

Tanta Fever Hospital

UNKNOWN

Sponsor Role: collaborator

Banha Fever Hospital

OTHER

Sponsor Role: collaborator

Alexandria University

OTHER

Sponsor Role: collaborator

University of Maryland, Baltimore

OTHER

Sponsor Role: lead

Responsible Party

Samer S. El-Kamary

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Samer El-Kamary, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

University of Maryland, College Park

George T Strickland, MD, PhD,

Role: STUDY_CHAIR

University of Maryland, College Park

Mohamed Hashem, MD

Role: STUDY_DIRECTOR

University of Maryland, College Park

Locations

Alexandria University Hospital

Alexandria, Alexandria Governorate, Egypt

Tanta Fever Hospital

Tanta, Gharbeya Governorate, Egypt

Banha Fever Hospital

Banhā, Kaluobeya Governorate, Egypt

Countries

Egypt

Other Identifiers

LE13K0.48

Identifier Type: -

Identifier Source: secondary_id

HP-00042363

Identifier Type: -

Identifier Source: org_study_id